

## HLAVNÍ TÉMA

TENEKTEPLÁŽA V LIEČBE ISCHEMICKEJ NCMP

a prematurely terminated randomized clinical trial. *Stroke*. 2010;41:707-711.

12. Huang X, Cheripelli BK, Lloyd SM, et al. Alteplase versus tenecteplase for thrombolysis after ischemic stroke (ATTEST): a phase 2, randomized, open-label, blinded endpoint study. *Lancet Neurology*. 2015;14:368-376.

13. Huang X, MacIsaac R, Thompson JL, et al. Tenecteplase versus alteplase in stroke thrombolysis: an individual patient data meta-analysis of randomized controlled trials. *International Journal of Stroke*. 2016;11:534-543.

14. Katsanos AH, Safouris A, Sarraj A, et al. Intravenous thrombolysis with tenecteplase in patients with large vessel occlusions: systematic review and meta-analysis. *Stroke*. 2021;52:308-312.

15. Kvistad CE, Næss H, Helleberg BH, et al. Tenecteplase versus alteplase for the management of acute ischemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomized, open-label, blinded endpoint, non-inferiority trial. *Lancet Neurology*. 2022;21:511-519.

16. Li S, Pan Y, Wang Z, et al. Safety and efficacy of tenecteplase versus alteplase in patients with acute ischemic stroke (TRACE): a multicenter, randomized, open label, blinded-endpoint (PROBE) controlled phase II study. *Stroke Vascular Neurology*. 2022;7:47-53.

17. Logallo N, Novotny V, Assmus J, et al. Tenecteplase versus alteplase for management of acute ischemic stroke (NOR-TEST): a phase 3, randomized, open-label, blinded endpoint trial. *Lancet Neurology*. 2017;16:781-788.

18. Ma Y, Xiang H, Busse JW, et al. Tenecteplase versus alteplase for acute ischemic stroke: a systematic review and meta-analysis of randomized and non-randomized studies. *J Neurol*. 2024;271:2309-2323.

19. Menon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischemic stroke in Canada (ACT): a pragmatic, multicenter, open-label, registry-linked, randomized, controlled, non-inferiority trial. *Lancet*. 2022;400:161-169.

20. Muir GFK, Ford I, Wardlaw JM, et al. Tenecteplase versus alteplase for acute stroke within 4.5 hours of onset: the second alteplase-tenecteplase trial evaluation for stroke thrombolysis (ATTEST-2). (2023).

21. Ouriel K. Safety and efficacy of various thrombolytic agents. *Reviews in Cardiovascular Medicine*. 2002;3(Suppl 2):S17.

22. Parsons M, Spratt N, Bivard A, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. *New England Journal of Medicine*. 2012;366:1099-1107.

23. Roaldsen MB, Eltoft A, Wilsgaard T, et al. Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicenter, open-label, randomized controlled trial. *Lancet Neurology*. 2023;22:117-126.

24. Ross AM. New plasminogen activators a clinical review. *Clinical Cardiology*. 1999;22:165-171.

25. Serebruany VL, Malinin AI, Callahan KP, et al. Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: The Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. *American Heart Journal*. 2003;145(4):636-642.

26. Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. *Clinical Pharmacokinetics*. 2002;41(15):1229-1245.

27. Wang Y, Li S, Pan Y, et al., TRACE-2 Investigators. Tenecteplase versus alteplase in acute ischemic cerebrovascular events (TRACE-2): a phase 3, multicenter, open-label, randomized controlled, non-inferiority trial. *Lancet*. 2023;401:645-654.

28. Xiong Y, Wang L, Li G, et al. Tenecteplase versus alteplase for acute ischemic stroke: a meta-analysis of phase III randomized trials. *Stroke Vascular Neurology*. 2023;28:svn-2023-002396.

# Už máte předplaceno?

## PŘEDPLATNÝM ČASOPISU NA ROK 2025 ZÍSKÁTE:

**20% slevu na kongresy\***  
pořádané společností SOLEN

\* platí pro kongresy uvedené v seznamu →



5x Neurologie pro praxi ve vaší schránce

Tematická suplementa

Přístup do archivu časopisu on-line

**Cena předplatného na rok 2025**

**1 980 Kč** (5 čísel/rok)

**Objednávejte**

www.neurologiepropraxi.cz  
predplatne@solen.cz

